The concern of generic challenges has consistently loomed around copyright’s blockbuster drug, Viagra, raising questions about the outlook of connected medicinal holdings. While early periods saw significant gains, the exclusivity expiration has opened the way for less expensive alternatives, potentially diminishing profitability and posing a rea